Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs MYK 491 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions
- Sponsors MyoKardia
- 27 Sep 2017 According to a MyoKardia media release, Based on results observed to date, MyoKardia has elected to include additional dose cohorts in the trial in order to further refine its understanding of MYK-491 pharmacokinetics and pharmacodynamics. Topline data from the 001 trial are now expected to be released by early 2018.
- 02 Feb 2017 According to a MyoKardia media release, first subject from the first cohort has been dosed .
- 02 Feb 2017 Status changed from planning to recruiting, as reported by a MyoKardia media release.